Oncology CT

Catch up on the top radiology content of the past week.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

Catch up on the most-well viewed radiology content in May 2025.

In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.

Catch up on the top radiology content of the past week.

In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.

The CleaRecon DL software reportedly removes streak artifacts that can occur with the use of cone-beam computed tomography (CBCT) during interventional radiology procedures.

Catch up on the top radiology content of the past week.

In comparison to American Joint Committee on Cancer (AJCC) TNM staging, an emerging CT-based scoring system for assessing early recurrence of pancreatic ductal adenocarcinoma demonstrated over a 22 percent higher AUC in testing and external validation cohorts in a new study.

The combination of the Aurora SPECT/CT system with AI-enabled Clarify DL image reconstruction reportedly offers the potential of enhanced image quality and streamlined workflows in nuclear medicine.

Catch up on the most-well viewed radiology content in April 2025.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in April 2025.

Catch up on the top AI-related news and research in radiology over the past month.

For elderly patients with lung cancer, a preoperative CT-based coronary artery calcium score > 40 was associated with a 53 percent higher risk of all-cause mortality after surgery, according to new study findings.

Catch up on the top radiology content of the past week.

Recently published research projected that 103,000 future cases of radiation-induced cancer would result from 93 million computed tomography (CT) exams performed in the United States in 2023.

In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.

In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).

Catch up on the top radiology content of the past week.

For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.

Catch up on the top radiology content of the past week.

LI-RADS category 5 (LR-5) assessment had an 11 percent higher AUC for detecting hepatocellular carcinoma (HCC) in patients with non-cirrhotic chronic hepatitis C (CHC) in comparison to those with cirrhotic CHC.

Catch up on the top radiology content of the past week.

The cLung-RADS v2022 model offered a greater than 16 percent increase in the AUC in comparison to Lung-RADS 1.0 and Lung-RADS v2022 systems for predicting the invasiveness of pure ground-glass nodules.

The Naeotom Alpha class of photon-counting computed tomography (PCCT) scanners emphasize significantly reduced scan times and enhanced detection of small abnormalities.

Catch up on the top radiology content of the past week.

The use of ivonescimab was correlated with a median 5.3-month improvement in progression-free survival (PFS) over pembrolizumab in patients with PD-L1 positive non-small cell lung cancer, according to CT and MRI findings from a phase 3 randomized multicenter trial.